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Abstract
Background: Anemia is a common clinical finding in HIV-infected patients and iron deficiency or redistribution
may contribute to the development of low hemoglobin levels. Iron overload is associated with a poor prognosis in
HIV and Hepatitis C virus infections. Iron redistribution may be caused by inflammation but possibly also by
hepatitis C co-infection. We examined the prevalence of anemia and its relation to mortality in a cohort of HIV
patients in a setting where injecting drug use (IDU) is a main mode of HIV transmission, and measured serum
ferritin and sTfR, in relation to anemia, inflammation, stage of HIV disease, ART and HCV infection.
Methods: Patient characteristics, ART history and iron parameters were recorded from adult HIV patients
presenting between September 2007 and August 2009 in the referral hospital for West Java, Indonesia. Kaplan-
Meier estimates and Cox’s regression were used to assess factors affecting survival. Logistic regression was used to
identity parameters associated with high ferritin concentrations.
Results: Anemia was found in 49.6% of 611 ART-naïve patients, with mild (Hb 10.5 - 12.99 g/dL for men; and 10.5 -
11.99 g/dL for women) anemia in 62.0%, and moderate to severe anemia (Hb < 10.5 g/dL) in 38.0%. Anemia
remained an independent factor associated with death, also after adjustment for CD4 count and ART (p = 0.008).
Seroprevalence of HCV did not differ in patients with (56.9%) or without anemia (59.6%). Serum ferritin
concentrations were elevated, especially in patients with anemia (p = 0.07) and/or low CD4 counts (p < 0.001), and
were not related to hsCRP or HCV infection. Soluble TfR concentrations were low and not related to Hb, CD4,
hsCRP or ART.
Conclusion: HIV-associated anemia is common among HIV-infected patients in Indonesia and strongly related to
mortality. High ferritin with low sTfR levels suggest that iron redistribution and low erythropoietic activity, rather
than iron deficiency, contribute to anemia. Serum ferritin and sTfR should be used cautiously to assess iron status
in patients with advanced HIV infection.
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Background
Anemia is a common clinical finding in HIV-infected
patients and is associated with advanced disease, lower
quality of life and higher mortality [1-4]. Many factors
may contribute to the development of anemia in HIV-
infected patients including nutritional deficiencies,
opportunistic infections, AIDS-related malignancies,
drug treatment and a direct effect of HIV on the bone
marrow [4]. Iron deficiency and inflammation-induced
iron maldistribution may also contribute to HIV-asso-
ciated anemia [5,6]. Due to the effects of inflammation,
iron is diverted from the circulation into the reticulo-
endothelial system and other storage sites. Apart from
inflammation, also HCV may possibly contribute to
redistribution of iron [7]. Hepcidin plays an important
role in these processes [8,9], by limiting the availability
of iron for hematopoiesis [10]. Iron maldistribution may
have another unwanted effect; it may increase suscept-
ibility to opportunistic infections, and accelerate disease
progression [7,11-14]. Indeed, iron overload is associated
* Correspondence: rudiw98@gmail.com
1Department of Internal Medicine Faculty of Medicine, Padjadjaran
University/Hasan Sadikin Hospital, Bandung, Indonesia
Full list of author information is available at the end of the article
Wisaksana et al. BMC Infectious Diseases 2011, 11:213
http://www.biomedcentral.com/1471-2334/11/213
© 2011 Wisaksana et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
with a poor prognosis in HIV and Hepatitis C virus
infections [7].
Serum concentrations of ferritin and soluble transfer-
rin receptor (sTfR) are frequently used to assess iron
status [15]. Low ferritin is an indicator of iron defi-
ciency, but as ferritin is also an acute phase reactant its
interpretation is difficult in the presence of inflamma-
tion. Levels of sTfR are predominantly determined by
the erythropoietic activity. Iron deficiency leads to
increased erythroblast numbers and increased TfR
expression and thus to considerably elevated sTfR levels.
In contrast, anemia of inflammation is characterized by
normal sTfR levels [6,16].
So far, limited and sometimes contradictory reports
have been published on ferritin and sTfR in HIV-
infected patients. High plasma ferritin concentrations
have been found among HIV-infected patients
[14,17-19], while other studies have reported low ferritin
concentrations [20,21]. Co-infection with hepatitis C
virus (HCV) may further complicate the assessment of
iron status, as HCV infection is associated with high
plasma ferritin concentrations [22]. With respect to
sTfR levels in HIV patients, two studies found sTfR
within the normal range [14,18], suggesting that sTfR is
not affected by HIV infection [12]. However, this is in
contrast with two other studies showing an increase in
sTfR concentrations after initiation of antiretroviral
treatment (ART) [19,21].
In the present study, we examined the prevalence of
anemia and its relation to mortality in a cohort of HIV
patients in a setting where injecting drug use (IDU) is
the main mode of HIV and HCV transmission [23]. We
also measured serum ferritin and sTfR, in relation to
anemia, inflammation, stage of HIV disease, ART and
HCV infection.
Methods
Setting and design
This cohort study was conducted at Hasan Sadikin hos-
pital as the referral hospital for HIV in West Java, Indo-
nesia. As one of the first 25 hospitals selected by the
Indonesian government to provide HIV-care, Hasan
Sadikin hospital has delivered free antiretroviral treat-
ment and PCP-prophylaxis since December 2004. Fol-
lowing WHO and national guidelines [24,25], ART is
indicated for patients presenting with WHO clinical
stage IV, WHO clinical stage III with a CD4 count
below 350/mm3, or WHO clinical stage I or II with a
CD4 count below 200/mm3. The national program pro-
vides a choice of nevirapine (NVP), efavirenz (EFV),
zidovudine (ZDV), stavudine (d4T) and lamivudine
(3TC) as first-line ART. For this study, we included all
HIV-positive patients above 14 years old presenting
between September 2007 and August 2009. All patients
signed informed consent and the study was approved by
the hospital ethical committee.
Data collection and laboratory examination
At time of first presentation at the hospital, all patients
(both ART-naïve and ART-experienced) have a ‘baseline
visit’ for structured interviewed and laboratory examina-
tion. Afterwards they come for scheduled visits, once-
monthly when on ART, three- to six-monthly when not
on ART. ART naïve patients were compared with
patients with a favorable effect of ART, excluding those
that with less than three months of ART, those who had
ever interrupted ART for more than one month, those
who had detectable HIV-RNA after six months ART,
and those taking 2nd ART. At presentation, data col-
lected included gender, age, history of injecting drug
use, body mass index (BMI, kg/m2), WHO stage, oral
candidiasis, and history of ART or tuberculosis (TB)
treatment. For ART-experienced patients, treatment
duration and regimen were recorded. During follow-up,
death was recorded from medical records.
Laboratory examinations included hemoglobin, red
cell indices (Cell Dyne 3000, Abbot) and manual reticu-
locyte counts. Reticulocyte index was defined as the reti-
culocyte percentage × (measured hematocrit/normal
hematocrit) [26]. Anti HCV antibodies were detected by
an electrochemiluminescence assay, ECLIA (Elecsys
2010, Roche) and CD4-cell count by flowcytometry (BD
Biosciences, Jakarta, Indonesia). In our setting, HIV-
RNA (real time PCR, Abbott, USA) is only measured in
patients taking ART, but not in ART naïve patients.
Between January 2008 and June 2008 we also measured
plasma ferritin (ECLIA method Elecsys 2010, Roche;
reference range 30-400 ng/mL for men and 35-150 ng/
mL for women), soluble Transferin Receptor (sTfR)
(enzyme Immunoassay method, Diamed, Eurogen; refer-
ence range 1870-2450 U/mL) and high sensitive C-Reac-
tive Protein (hsCRP) (immunoturbidimetry method,
Hitachi 912, Roche; reference < 5 mg/L) in newly diag-
nosed patients. We defined ferritin as ‘high’ if it was
above the upper reference value.
Data analysis and statistics
WHO/ACTG criteria were used to define mild (Hb 10.5 -
12.99 g/dL for men; and 10.5 - 11.99 g/dL for women),
moderate (Hb 8.0 - 10.49 g/dL) and severe (Hb < 8.0 g/
dL) anemia [27,28]. As diagnosis of TB is difficult in HIV-
positive patients in this setting due to its paucibacillary
nature and the fact that many patients are unable to
expectorate sputum [29], we considered all patients receiv-
ing TB treatment within three months after presentation
as having TB co-infection. Mortality data were derived
from clinical files, reports from community organizations
or phone interviews from the clinic. Patients not returning
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for more than three months without confirmation of death
or transfer were considered lost to follow-up. Data are
presented as proportions or median with inter quartile
range if not normally distributed. Categorical and continu-
ous data were compared using the Chi-squared and Krus-
kal-Wallis tests respectively. Progression to death was
measured by Kaplan-Meier estimates with Cox-regression
to examine factors in baseline visits that affecting survival.
Ferritin and sTfR concentration divided based on manu-
facturers reference values. Cox-proportional hazard
regression model was used to investigate association
between iron inflammatory parameters and mortality.
Clinical parameters were examined as a possible determi-
nant of mortality and high ferritin concentrations using
logistic regression models. Variables which were signifi-
cantly associated in univariate analysis (p < 0.05) were
used in the final backward stepwise multivariate regression
model. Proportionality was first assessed by generating
time dependent covariates of interactions between predic-
tors and survival function. Log-transformed ferritin and
sTfR values were used to examine the relation between
ferritin, sTfR, CRP and CD4. All statistical analysis was
done using SPSS version 16.0.2 and Prism 4 for Windows.
Results
Patient characteristics
A total number of 869 HIV positive patients were
enrolled in this study, 70.3% (611) of whom were ART
naïve, and 258 (29.7%) of whom were on ART (Figure
1). Table 1 shows the baseline patient characteristics.
ART naïve patients
In this group, mild, moderate and severe anemia was
present in 30.4%, 14.1%, and 4.6%, respectively, while
hemoglobin levels were missing for 7 patients (1.1%).
Clinical characteristics of ART-naive patients, stratified
according to anemia category are presented in Table 1.
Most ART-naive patients presented with advanced HIV
infection or AIDS; 66.7% had a CD4-cell count below
200 cells/mm3, and 62.8% were in WHO stage III/IV.
Malnourishment, defined as a body mass index (BMI)
below 18.5 kg/m2 was found in 38.0% of patients; severe
Figure 1 Follow-up diagram of the cohort HIV-patients in Hasan Sadikin Hospital Bandung, September 2007-August 2009 (n = 869).
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malnourishment (BMI < 16 kg/m2) was found in 12.7%
of patients. One fifth (21.3%) of patients were already on
TB treatment or started TB treatment within 3 months
of presentation, 58.5% were co-infected with HCV, and
oral candidiasis was diagnosed in 27.8% of patients.
Anemia in ART-naïve HIV patients was mostly nor-
mocytic, normochromic and characterized by a normal
or low reticulocyte index suggesting ‘anemia of chronic
disease’ as the main cause. Anemia was associated with
a low CD4-cell count (p < 0.001), and TB treatment (p
< 0.001) (Table 1). Hepatitis C co-infection prevalence
was not different in patients with and without anemia
(56.9% vs. 59.6%, p = 0.54). During follow-up, 314
patients (51.4%) started ART after a median of 28 days
(IQR: 19-55). The majority of patients (70.1%), none of
whom had moderate or severe anemia, were started on
a ZDV-containing regimen. From this group, 13.6%
developed anemia during follow-up and were subse-
quently switched from ZDV to d4T.
Mortality in ART-naïve patients
Anemia was associated with increased mortality during
follow-up. When 611 ART-naïve patients were followed
for a median of 4.4 (IQR: 0.0-12.1) months (total follow-
up: 335 person-years), 45 patients (7.4%, IQR: 5.3%-
9.5%) died and 121 (19.8%, IQR: 16.6%-23.0%) were lost
to follow-up (Figure 1). Mortality (75.6% of the total)
and loss to follow-up (92.6% of the total) were highest
in the first 6 months after presentation. Using Kaplan-
Meier estimates, the survival rates at 6 months were
98.6% (95% CI: 97.3-99.9%) for patients without anemia,
95.1% (92.0-98.5%) for patients with mild anemia and
82.5% (75.5-89.4%) for patients with moderate or severe
anemia (P < 0.001; Figure 2). Beside a CD4 cell count
below 50/mm3 (HR: 5.7, IQR: 1.6-17.8, p = 0.003), mod-
erate to severe anemia remained independently asso-
ciated with an increased risk of death in multivariate
analysis (HR: 6.5, IQR: 2.0-21.2, p = 0.002) (Table 2),
This association remained significant after eliminating
subjects with tuberculosis co-infection, which is an
important risk factor for death.
Iron status parameters in ART-naïve patients
Serum ferritin, sTfR, CRP and reticulocyte index were
measured in a subgroup of 141 randomly selected
patients. ART-naïve patients (n = 95) with available iron
parameters had very high plasma ferritin concentrations
(median 641 ng/mL, IQR: 242-1296), moderately
Table 1 Characteristics of ART-naïve and experienced HIV-patients in Hasan Sadikin Hospital, September 2007 -
August 2009 (n = 869)
Characteristics ART naïve ART experienced p
value
Total
n = 611
No
anemia
n = 304
Mild
n = 186
Moderate-
severe
n = 114
Total
n = 258
No
anemia
n = 216
Mild
n = 37
Moderate-
severe
n = 5
Male sex, % 68.2 67.1 68.8 69.3 81.6 83.6 73.0 60.0 < 0.001
Median age, yrs (IQR) 28 (26-31) 28 (25-30) 29 (26-32) 29 (26-34) 29 (26-32) 29 (26-32) 30 (26-34) 31 (29-31) 0.45
Median BMI, kg/m2
(IQR)
19.5
(17.3-22.0)
19.8
(17.8-22.6)
19.1
(16.9-21.6)
19.6
(16.8-21.8)
20.3
(18.6-22.5)
20.4
(18.5-22.5)
20.2
(18.5-22.3)
17.8
(15.7-22.1)
0.63
History of IDU, % 63.1 64.9 61.8 61.0 84.4 86.5 78.4 40.0 < 0.001
Anti HCV (+), % 58.5 59.6 61.3 50.0 80.0 84.0 64.7 25.0 < 0.001
Median CD4, cells/
mm3
(IQR)
76
(20-305)
232
(66-406)
45
(15-144)
17
(6-45)
272
(201-395)
280
(220-425)
195
(128-314)
190
(72-375)
< 0.001
TB treatment, % 21.3 6.3 27.4 50.9 3.9 2.8 5.4 40.0 < 0.001
Oral Candidiasis, % 27.8 21.8 35.4 31.4 3.3 2.0 5.7 40.0 < 0.001
Median MCV (IQR) (fl) 84.3
(80.3-87.5)
85.8
(82.8-88.6)
82.8
(77.6-86.4)
81.3
(76.0-84.7)
108.5
(103.0-114.0)
109.0
(104.0-
114.0)
108.0
(99.8-114.0)
88.4
(81.0-100.1)
< 0.001
Median MCH (IQR)
(pg)
28.9
(27.3-30.2)
29.5
(28.2-30.5)
28.4
(25.9-29.8)
27.8
(25.7-29.2)
38.4
(36.0-40.6)
38.4
36.3-40.7)
39.0
(34.2-40.5)
29.2
(27.7-33.8)
0.58
Reticulocyte index
(%)
0.8
(0.6-1.5)
1.0
(0.6-1.8)
0.8
(0.6-1.0)
1.0 (0.5-2.7) 0.8 (0.6-1.0) 0.9 (0.7-1.4) 0.6 (0.5-1.0) 1.0 (1.0-1.0) 0.02
* p value for difference between ART-naïve and experienced group
Mild anemia: Hb 10.5 - 12.99 g/dL for men; and 10.5 - 11.99 g/dL for women, moderate-severe anemia: Hb < 10.5 g/dL.
TB treatment: receive TB treatment in presentation or within 3 months of presentation
Anemia status missing in 7 patients, gender in 3 patients, age in 1 patients, BMI in 151 patients, IDU status in 46 patients, anti HCV in 117 patients, CD4 in 13
patients, oral candidiasis in 94 patients, reticulocyte index only available from 184 patients
BMI: body mass index; IDU: injecting drug user; HCV: Hepatitis C virus; TB: tuberculosis; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; IQR:
interquartile range.
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elevated CRP concentrations (median 6 mg/mL, IQR: 2-
34), low sTfR concentrations (median 1014 U/mL, IQR:
736-1322), and normal reticulocyte counts (median
0.8%, IQR: 0.6-1.5%).
Very high ferritin concentrations were found in sub-
jects with CD4 counts below or equal to 50 cells/mm3
(median 1078 mg/ml, IQR: 550-1824) compared to sub-
jects with CD4 counts above 50 cells/mm3 (median 279
Figure 2 Kaplan-Meier survival curve for ART-naïve HIV-infected patients with no (black), mild (dark grey) or moderate/severe anemia
(light grey) (n = 604).
Table 2 Multivariate analysis for factors related to six-month mortality among ART-naïve patients (n = 611) in Hasan
Sadikin Hospital, September 2007 - August 2009
Base Analysis Sensitivity Analysis
n Mortality Univariate Multivariate Multivariate
HR (95% CI) p value HR adjusted (95% CI) p value HR adjusted (95% CI) p value
Gender
Female 194 5 1 1 1
Male 416 29 2.8 (1.1-7.4) 0.03 1.5 (0.5-4.3) 0.46 1.8 (0.5-6.2) 0.32
Age (years old)
< 29 317 11 1 1 1
≥29 294 23 2.3 (1.1-4.9) 0.02 1.6 (0.7-3.5) 0.24 1.4 (0.5-6.2) 0.49
CD4 (cells/mL)
> 50 353 4 1 1 1
≤ 50 248 29 11.6 (4.0-33.3) < 0.001 5.7 (1.8-17.8) 0.003 6. 1 (1.6-23.1) 0.008
BMI (kg/m2)
≥18.5 183 9 1
< 18.5 299 13 1.1 (0.5-2.7) 0.77
Anemia, (%)
No anemia 304 4 1 1 1
Mild 186 10 3.8 (1.2-12.6) 0.03 2.2 (0.6-7.6) 0.21 2.6 (0.6-11.1) 0.19
Moderate and severe 114 20 16.0 (5.3-47.9) < 0.001 6.5 (2.0-21.2) 0.002 10.9 (2.7-44.3) 0.001
History of IDU, (%)
No 209 11 1
Yes 357 21 1.1 (0.5-2.4) 0.76
ART, (%)
No 324 14 1
Yes 287 20 1.7 (0.8-3.3) 0.12
*Data were missing for gender (n = 1), CD4 (n = 10), BMI in 482 patients (n = 129), anemia status (n = 7), history of IDU (n = 45).
Sensitivity analysis: subjects with TB treatment within 3 months presentation excluded from analysis
Mild anemia: Hb 10.5 - 12.99 g/dL for men; and 10.5 - 11.99 g/dL for women, moderate-severe anemia: Hb < 10.5 g/dL.
ART: receive ART within 6 of presentation.
BMI, body mass index; IDU: injecting drug user; ART, anti retroviral; HR, hazard ratio;
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mg/ml, IQR: 41-465, p < 0.001), and in subjects with
moderate-severe anemia (median 1223 mg/ml, IQR:
519-2764) compared to subjects without (median 436
mg/ml, IQR: 245-1296. p = 0.07) or with mild anemia
(median 532 mg/ml, IQR: 194-1099, p = 0.01). Moder-
ately elevated hsCRP levels were also found in subjects
with CD4 counts below or equal to 50 cells/mm3 (med-
ian 12.2 mg/L, IQR: 2.0-63.2) compared to subjects with
CD4 counts above 50 cells/mm3 (median 4.9 mg/ml,
IQR: 1.5-17.2, p = 0.08), and in subjects with moderate-
severe anemia (median 18.4 mg/ml, IQR 4.5-94.4) com-
pared to subjects without (median 2.0 mg/ml, IQR: 1.4-
5.4, p = 0.001) or with mild anemia (median 6.0 mg/ml,
IQR: 1.2-27.8, p = 0.03). Subjects with high ferritin, high
hsCRP or low sTfR concentrations showed a higher
mortality during follow-up, although this was not statis-
tically significant (Table 3). Low ferritin levels (< 30 mg/
ml) were found in 6.3% of patients, all were women
with a CD4 cell count above 200 cells/mm3. There was
a significant negative correlation between ferritin con-
centrations and CD4 count (Figure 3).
Predictors of hyperferritinemia in ART-naïve patients
were subsequently determined in a univariate and multi-
variate model (Table 4). CD4 cell count below 50/mm3
and hsCRP > 5 mg/L were associated with hyperferriti-
nemia after correction for gender, degree of anemia, and
HCV co-infection. After exclusion of patients with
tuberculosis co-infection, low CD4 count was the only
factor associated with hyperferritinemia.
ART experienced patients
At time of enrollment in the cohort, 258 patients were
already taking 1st line ART, for a median of 24.0 months
(range: 3.3 - 96.3 months). The majority of patients were
on a ZDV containing regimens (62.8%), the others on a
d4T containing regimen. Anemia was less common in
patients taking ART: 14.3% had mild, 1.9% had moder-
ate, and no patient had severe anemia (p < 0.001) (Table
1). The use of ZDV was associated with anemia: among
patients taking ZDV, 20.3% had anemia, compared with
7.4% among those who were not taking ZDV (p = 0.01).
During a median 19.8 months (IQR: 9.8-20.0), 2 (0.8%)
Table 3 Associations between iron and inflammatory parameters and mortality among ART-naïve patients (n = 95) in
Hasan Sadikin Hospital, September 2007 - August 2009
Single Multiple*
n mortality HR (95% CI) p value HR (95% CI) p value
Ferritin
Low-normal 31 4 1 1
High 64 16 1.8 (0.6-5.4) 0.29 1.3 (0.4-4.6) 0.68
sTfR
Normal-high 10 4 1 1
Low 85 16 2.2 (0.7-6.6) 0.16 1.7 (0.5-5.3) 0.38
hsCRP
< 50 mg/L 41 5 1 1
> 50 mg/L 54 15 2.2 (0.1-6.1) 0.12 2.1 (0.6-7.3) 0.24
*Cox proportional hazard models adjusted for CD4 cell count (< 50, > 50 cells/mm3), age (< 29, > 29 years old), anemia (no anemia Hb > 13 g/dl for men and >
12 g/dl for women, mild Hb < 10.5 - 12.99 g/dL for men; and < 10.5 - 11.99 g/dL for women, moderate-severe anemia: Hb < 10.5 g/dL), and gender.
Ferritin: High > 400 ng/mL for men or > 150 ng/mL for women, low-normal < 400 ng/mL for men or < 150 ng/mL for women; sTfR: Low < 1870 U/mL; normal-
high > 1870 U/mL
HR, Hazard ration; CI: confidence interval; hsCRP, high sensitive C-reactive protein.
 
Figure 3 Association between CD4 cell count and (a) Ferritin
and (b) soluble Transferin receptor (sTfR) plasma
concentrations in patients with (black) and without ART (grey).
The lines are based on linear regression (n = 137).
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ART experienced patients died and 26 (10.1%) were lost
to follow-up.
Patients taking ART seemed to have lower plasma fer-
ritin concentrations (median 304.1 ng/mL, IQR; 160.7-
574.6) compared to ART-naïve patients, although this
was not statistically significant (p = 0.12). In addition,
they had lower hsCRP values (median 3.0 mg/mL, IQR:
0.9-6.3, p = 0.02), but similarly low sTfR concentrations
(median 1378.5 U/mL, IQR: 1104.3-1798.5, p = 0.95)
compared to ART-naïve patients. Duration of ART was
not associated with plasma concentrations of ferritin or
sTfR (data not shown). There was a significant negative
correlation between ferritin concentrations and CD4
count in ART-naïve patients, but not in patients taking
ART (Figure 3).
Discussion
The results from our study indicate that anemia is
highly prevalent among HIV patients in Indonesia and
that moderate to severe anemia is strongly related to
mortality. This is in line with findings from other stu-
dies [2,3,30-32]. We also report serum concentrations of
ferritin and sTfR, both of which are often used for
assessment of iron status. High serum ferritin concen-
trations were found, especially in patients with CD4 cell
counts below 200 cells/mm3. Iron redistribution in the
setting of a prolonged acute phase response is most
likely responsible for this observation and this may
explain the reported iron excess in the liver, bone mar-
row and other organs during the advanced stages of
HIV [33]. Concentrations of CRP were however only
moderately elevated and did not correlate well with fer-
ritin concentrations. Although CRP is the most com-
monly used indicator of inflammation in daily practice,
other acute phase response proteins such as a-1-acid-
glycoprotein (AGP) may better reflect serum ferritin
changes in inflammation because AGP remains elevated
for a much longer time in sub-clinical chronic infections
compared to CRP [15,34].
We found that sTfR concentrations were generally low
and not related to CD4 count. This finding is in con-
trast to studies that showed that sTfR is not affected by
HIV infection, even though these studies also report
that sTfR alone has little value for differentiating anemia
in the presence of inflammation [12,35,36]. We hypothe-
size that low sTfR concentrations more likely reflects
the presence of some degree of bone marrow suppres-
sion by HIV. Together, these findings suggest that both
serum ferritin and sTfR concentrations may not be reli-
able indicators of iron status in advanced HIV infection.
The prevalence of anemia was more than 40% in our
untreated HIV-infected patients, more or less similar to
Table 4 Multivariate analysis for factors related to high-ferritin concentrations among ART-naïve patients (n = 95) in
Hasan Sadikin Hospital, September 2007 - August 2009
Base analysis Sensitivity analysis
n high ferritin Univariate Multivariate Multivariate
OR
(95% CI)
p value OR adjusted
(95% CI)
p value OR adjusted (95% CI) p value
Gender
Female 27 12 1 1 1
Male 68 52 4.1 (1.6-10.4) 0.004 1.5 (0.5-5.1) 0.47 1.8 (0.50-6.2) 0.39
Anemia
No anemia 15 10 1
Mild 56 35 0.8 (0.3-2.8) 0.77
Moderate - severe 24 19 1.9 (0.4-8.2) 0.39
hsCRP (mg/L)
< 5 41 21 1 1 1
> 5 54 43 3.7 (1.5-9.2) 0.004 3.8 (1.3-10.9) 0.01 2.8 (0.9-8.4) 0.07
CD4 (cells/mL)
> 50 33 12 1 1 1
0-50 60 51 9.9 (3.6-27.0) < 0.001 10.0 (3.5-28.8) < 0.001 6.8 (2.2-20.3) 0.001
Anti HCV
Negative 19 9 1
Positive 36 25 2.5 (0.8-7.9) 0.11
*CD4 cell counts were missing in 2 patients, HCV serostatus in 40 patients.
Sensitivity analysis: subjects with TB treatment within 3 months presentation excluded from analysis
High ferritin: > 400 ng/mL for men or > 150 ng/mL for women
Mild anemia: Hb 10.5 - 12.99 g/dL for men; and 10.5 - 11.99 g/dL for women, moderate-severe anemia: Hb < 10.5 g/dL.
ART, anti retroviral; OR, odd ratio; hsCRP, high sensitive C-reactive protein; HCV, hepatitis virus C.
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studies from outside Indonesia [2,18,30,37]. Severe ane-
mia was noticed in nearly 5% of our patients and this
was higher compared to previous data from Europe [2]
or Asia [3] but lower compared to a study from Africa
[30]. Differences between the levels of immunodefi-
ciency in the different studies may account for these dif-
ferences. Our study also demonstrates that anemia is
strongly related to increased mortality, as reported by
others [2,3,30,31]. Interestingly, we found that this was
also true after correction for CD4 cell count, indicating
that anemia is an independent factor for HIV disease
progression.
Measurement of iron parameters in a sub-group of
patients revealed marked elevations in plasma ferritin, in
line with earlier studies [14,17-19,35]. Our study shows
that high ferritin levels are strongly (and inversely)
related to CD4 cell numbers but not to gender, HCV
co-infection nor CRP as a marker of inflammation, as
has been suggested by others [19,37]. Apart from the
prolonged acute phase response, the inverse relation
between ferritin and CD4 cell count may also be caused
by increased oxidative stress [38] related to depletion of
CD4 cells [39]. Furthermore, The HIV virus itself may
increase ferritin levels as HIV-1 Nef protein directly
down-regulates the hemochromatosis protein HFE and
as such causes iron accumulation [40]. However, the lat-
ter hypothesis was not supported by a study among HIV
patients in Thailand, which reported no relation
between serum ferritin concentrations and plasma HIV
RNA [20]. Finally, the role of inflammation cannot be
completely excluded since inflammatory pathways that
do not include IL-6 and CRP can lead to high ferritin
concentrations [41]. Interestingly, the inverse relation
between ferritin levels and CD4 cell numbers disap-
peared after ART. This could be due to the effect of
ART on oxidative stress, plasma HIV-RNA and/or
inflammation. Our results argue against an important
role of HCV as no relation was found between ferritin
and HCV infection, although the number of subjects in
whom all parameters were measured was limited.
Low ferritin levels (< 30 mg/ml) indicating iron defi-
ciency were found in 6.3% of our patients and in 18.5%
of the female patients. In previous studies from United
States, iron deficiency anemia was found in 20% of HIV
infected female injecting drug users [42], and iron sup-
plementation was found to reduce anemia without
adverse effects on HCV co-infection or plasma HIV-
RNA [43]. However, iron supplementation should be
done carefully and only in patients with iron deficiency
as iron overload is associated with a poor prognosis of
HIV-1 and hepatitis C virus infections and with growth
of pathogenic microorganism [7]. Indeed, excess mortal-
ity was reported among HIV-infected patients receiving
low-dose oral iron with dapsone for Pneumocystis carinii
pneumonia prophylaxis [11]. In our study, we did not
find a significant relation between plasma ferritin level
and mortality, even though those who died on average
had two-fold higher plasma ferritin levels.
Unlike ferritin, sTfR levels showed no association with
CD4 cell counts, neither among ART-naïve nor among
ART-experienced patients. Furthermore, sTfR levels
were not different in anemic versus non-anemic sub-
jects. Our sTfR levels seem slightly low, especially in
ART-naïve patients suggesting that reduced erythropoi-
esis may contribute to the development of anemia,
although no relation was found between sTfR levels and
the presence or degree of anemia. Plasma sTfR concen-
trations were not associated with mortality during fol-
low-up. This was also found in other studies which
showed an increase of sTfR following ART [19,21], and
no relation between sTfR levels and disease progression
[19].
Our study has several limitations as it was observa-
tional, and as iron parameters were only measured in a
subset of patients. Furthermore, no data are available on
food or micronutrient intake which might affect iron
status, and on occurrence of other opportunistic infec-
tions causing anemia. Tuberculosis could be important
cause of anemia and could confound the results,
although sensitivity analysis showed this was not the
case. Furthermore we did not adjust ferritin concentra-
tions for circulating HIV-RNA which are not measured
routinely in ART-naïve patients. To be able to see the
effects of ART on iron parameters, we excluded non-
adherent patients. Loss to follow-up may have affected
the estimated mortality, although we believe this did not
affect our conclusions, since there was no significant dif-
ference in clinical characteristics including degree of
anemia and CD4 cell count between patients with and
without follow-up (data not shown).
Conclusion
We can conclude that anemia, although usually mild, is
highly prevalent in this setting and strongly related to
immune-deficiency and mortality. Iron maldistribution
and not iron deficiency seems to underlie the develop-
ment of anemia while the role of compromised erythro-
poiesis and HCV co-infection seems limited.
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